Ifosfamide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1988
- First approval year
- 1988
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Ifosfamide
- Molecular weight
- 261.09
- Structure (SMILES)
- O=P1(NCCCl)OCCCN1CCCl
- ifex
- Ifex
- ifosfamide
- Ifosfamide
- ifsofamide
- Ifsofamide
- mitoxana
- Mitoxana
- albumin bound paclitaxel nab ptx ifosfamide and cisplatin
- ifosfamida
- Ifosfamida
- ifosfamide
- Ifosfamide
- IFOSFAMIDE [EP IMPURITY]
- IFOSFAMIDE [EP MONOGRAPH]
- IFOSFAMIDE [HSDB]
- ifosfamide [INN]
- IFOSFAMIDE [JAN]
- IFOSFAMIDE [MART.]
- IFOSFAMIDE [MI]
- IFOSFAMIDE [ORANGE BOOK]
- IFOSFAMIDE [USAN]
- IFOSFAMIDE [USP MONOGRAPH]
- IFOSFAMIDE [USP-RS]
- IFOSFAMIDE [VANDF]
- Ifosfamide [WHO-DD]
- ifosfamide and mesna
- ifosfamide ep impurity
- ifosfamide ep monograph
- ifosfamide for injection
- Ifosfamide for Injection
- ifosfamide hsdb
- ifosfamide inn
And 28 more, listed on the interactive page.
- ATC classification codes
- L01AA06
Sources for recorded values
- CAS registry numbers
- 3778-73-2
- ChEMBL ID
- CHEMBL1024
- InChIKey
- HOMGKSMUEGBAAB-UHFFFAOYSA-N
- PubChem compound IDs
- 3690
- RxNorm IDs (RxCUI)
- 5657
- FDA ingredient codes (UNII)
- UM20QQM95Y
- Applicant
- BAXTER HLTHCARE
- Approval date
- 14 Aug 1987
- Application number
- NDA019763
- Patents
- 0
- Designations
- 3
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- ifosfamide
- Type
- Synthetic organic
- Drug name stem
- -fos-; -fosfamide
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Pheochromocytoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000239
- Subject identifier
- D010673
- Condition
- Rhabdomyosarcoma, Alveolar
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000248
- Subject identifier
- D018232
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Rhabdomyosarcoma, Embryonal
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000437
- Subject identifier
- D018233
- Condition
- Neoplasms, Germ Cell and Embryonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000514
- Subject identifier
- D009373
- Condition
- Leiomyosarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000564
- Subject identifier
- D007890
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Liposarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000569
- Subject identifier
- D008080
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Osteosarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Sarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
And 51 more, listed on the interactive page.
- Condition identifier
- EFO_0000174
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000514
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000637
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Condition identifier
- EFO_0002914
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003893
- Condition identifier
- EFO_0003967
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004252
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004281
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000082
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000158
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000601
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001365
- Highest recorded phase
- 2
And 135 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Country
- United States
- Event
- acute myeloid leukaemia
- Reports
- 118
- Reporting signal score
- 254.919
- Event
- anaemia
- Reports
- 416
- Reporting signal score
- 265.129
- Event
- aplasia
- Reports
- 43
- Reporting signal score
- 107.9
- Event
- bone marrow failure
- Reports
- 220
- Reporting signal score
- 394.823
- Event
- cardiotoxicity
- Reports
- 89
- Reporting signal score
- 178.314
- Event
- cystitis haemorrhagic
- Reports
- 56
- Reporting signal score
- 128.256
- Event
- cytokine release syndrome
- Reports
- 54
- Reporting signal score
- 79.8812
- Event
- cytopenia
- Reports
- 67
- Reporting signal score
- 105.24
- Event
- diffuse large b-cell lymphoma
- Reports
- 67
- Reporting signal score
- 144.266
- Event
- diffuse large b-cell lymphoma recurrent
- Reports
- 60
- Reporting signal score
- 187.149
- Event
- diffuse large b-cell lymphoma refractory
- Reports
- 45
- Reporting signal score
- 183.19
- Event
- disease progression
- Reports
- 288
- Reporting signal score
- 288.531
- Event
- disease recurrence
- Reports
- 118
- Reporting signal score
- 159.332
- Event
- encephalopathy
- Reports
- 335
- Reporting signal score
- 733.816
- Event
- fall
- Reports
- 11
- Reporting signal score
- 96.3354
- Event
- fanconi syndrome
- Reports
- 50
- Reporting signal score
- 145.326
- Event
- febrile bone marrow aplasia
- Reports
- 60
- Reporting signal score
- 122.938
- Event
- febrile neutropenia
- Reports
- 1,004
- Reporting signal score
- 2,419.23
- Event
- haematotoxicity
- Reports
- 142
- Reporting signal score
- 323.812
- Event
- headache
- Reports
- 49
- Reporting signal score
- 99.9818
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 89.7629
- Event
- leukopenia
- Reports
- 259
- Reporting signal score
- 318.736
- Event
- malignant neoplasm progression
- Reports
- 211
- Reporting signal score
- 222.927
- Event
- mucosal inflammation
- Reports
- 302
- Reporting signal score
- 593.037
- Event
- myelodysplastic syndrome
- Reports
- 168
- Reporting signal score
- 370.687
And 19 more, listed on the interactive page.
- NCT00001209
- NCT00001300
- NCT00002516
- NCT00002546
- NCT00002601
- NCT00002641
- NCT00002764
- NCT00002791
- NCT00002804
- NCT00002898
- NCT00002974
- NCT00003052
- NCT00003128
- NCT00003212
- NCT00003776
- NCT00003937
- NCT00006734
- NCT00020566
- NCT00023738
- NCT00030784
- NCT00061893
- NCT00061984
- NCT00072280
- NCT00077285
- NCT00093509
And 244 more, listed on the interactive page.
- Dose
- 1.2 grams per m2 per day for 5 consecutive days
- Route
- Intravenous
- How often
- Every 3 weeks or after recovery from hematologic toxicity
- Administer as a slow infusion lasting at least 30 minutes
- Hydrate with at least 2 liters of oral or intravenous fluid per day for bladder toxicity prevention
- Use Mesna to reduce hemorrhagic cystitis risk
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 1
- Polar surface area
- 41.57
- Calculated partition coefficient (ALogP)
- 1.88
- Calculated partition coefficient (XLogP)
- 0.9
- Prodrug
- Yes
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 14
- Molecular formula
- C7H15Cl2N2O2P
- Monoisotopic mass
- 260.0248201
- Natural product
- Yes
- 0143-9530
- 0143-9531
- 0338-3991
- 0338-3993
- 10019-925
- 10019-926
- 10019-927
- 10019-929
- 21586-211
- 63323-142
- Recorded assays
- 4,989
- Active assays
- 352
- Confirmatory
- Other
- Screening
- Antineoplastic Agents, Alkylating
Related records
Trials (404)
- A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
- A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
- A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
- A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer
- A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
- A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
- A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
- A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
- A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma
- A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall
- A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
- A Study of Auxora in Patients With Critical COVID-19 Pneumonia
Approved for (7)
- Cancer
- Connective and soft tissue neoplasm
- Malignant testicular germ cell tumor
- Neoplasm
- Neoplasm of testis
- Ovarian neoplasm
- Testicular cancer
In development for (145)
- Acute lymphoblastic leukemia Phase 3
- Acute monocytic leukemia Phase 2
- Acute myeloid leukemia Phase 2
- Adrenal gland pheochromocytoma Phase 3
- Adult fibrosarcoma Phase 3
- Adult liposarcoma Phase 3
- Alveolar rhabdomyosarcoma Phase 2
- Alveolar soft part sarcoma Phase 3
- Anaplastic large cell lymphoma Phase 2
- Anaplastic meningioma Phase 2
- Angiosarcoma Phase 1
- B-cell chronic lymphocytic leukemia Phase 2
- B-cell non-Hodgkin lymphoma Phase 2
- Bone sarcoma Phase 2
- Breast cancer Phase 2
- Burkitt lymphoma Phase 2
- Carcinoma Phase 3
- Carcinosarcoma Phase 3
- Central nervous system germ cell tumor Phase 2
- Central nervous system neoplasm Phase 3
Other linked conditions (5)
- Bone cancer
- Central nervous system disorder
- Prostate cancer
- Prostate neoplasm
- Reticulum cell sarcoma